EDITORS' NOTE

For the oncologist from The Oncologist

The Oncologist 2002; 7: 389; doi:10.1634/theoncologist.7-5-389
[Full Text] [PDF]  

Gleevec^TM for the Treatment of Chronic Myelogenous Leukemia: U.S. Food and Drug Administration Regulatory Mechanisms, Accelerated Approval, and Orphan Drug Status

Martin H. Cohen, Marie L. Moses, Richard Pazdur
The Oncologist 2002; 7: 390-392; doi:10.1634/theoncologist.7-5-390
[Abstract] [Full Text] [PDF]  

U.S. Food and Drug Administration Drug Approval Summaries: Imatinib Mesylate, Mesna Tablets, and Zoledronic Acid

Martin H. Cohen, Ramzi Dagher, Donna J. Griebel, Amna Ibrahim, Alison Martin, Nancy S. Scher, Gerald H. Sokol, Grant A. Williams, Richard Pazdur
The Oncologist 2002; 7: 393-400; doi:10.1634/theoncologist.7-5-393
[Abstract] [Full Text] [PDF]  

Clinical Trial Design for Target-Based Therapy

Elizabeth Fox, Gregory A. Curt, Frank M. Balis
The Oncologist 2002; 7: 401-409; doi:10.1634/theoncologist.7-5-401
[Abstract] [Full Text] [PDF]  

Phase II Trial of Weekly Vinorelbine and Trastuzumab as First-Line Therapy in Patients with HER2⁺ Metastatic Breast Cancer

Mohammad Jahanzeb, Joanne E. Mortimer, Furhan Yunus, David H. Irwin, James Speyer, Alan J. Koletsky, Paula Klein, Tariq Sabir, Lori Kronish
The Oncologist 2002; 7: 410-417; doi:10.1634/theoncologist.7-5-410
[Abstract] [Full Text] [PDF]  

Efficacy of a Primary Chemotherapy Regimen Combining Vinorelbine, Epirubicin, and Methotrexate (VEM) as Neoadjuvant Treatment in 89 Patients with Operable Breast Cancer

Isabelle Van Praagh, Hervé Cure, Bernard Leduc, Sabine Charrier, Guillaume Le Bouedec, Jean-Louis Achard, Jean-Pierre Ferriere, Viviane Feillel, Monique de Latour, Jacques Dauplat, Philippe Chollet
The Oncologist 2002; 7: 418-423; doi:10.1634/theoncologist.7-5-418
[Abstract] [Full Text] [PDF]  

5-HT₃-Receptor Antagonists for the Treatment of Nausea and Vomiting: A Reappraisal of Their Side-Effect Profile

Susan Goodin, Regina Cunningham
The Oncologist 2002; 7: 424-436; doi:10.1634/theoncologist.7-5-424
[Abstract] [Full Text] [PDF]  

CA125 Response: Can it Replace the Traditional Response Criteria in Ovarian Cancer?

A.E. Guppy, G.J.S. Rustin
The Oncologist 2002; 7: 437-443; doi:10.1634/theoncologist.7-5-437
[Abstract] [Full Text] [PDF]  

A Phase I Trial of Weekly Paclitaxel Plus Prolonged Oral Eniluracil/5-Fluorouracil in Patients with Refractory Malignancies

Suzanne F. Jones, F. Anthony Greco, John D. Hainsworth, Jeffrey W. Patton, John H. Barton, Noel T. Willcutt, Margaret N. Baker, Paul V. McGuirt, Jeremey Levin, Howard A. Burris, III
The Oncologist 2002; 7: 444-450; doi:10.1634/theoncologist.7-5-444
[Abstract] [Full Text] [PDF]  

Aberrant DNA Methylation in Lung Cancer: Biological and Clinical Implications

Sabine Zöchbauer-Müller, John D. Minna, Adi F. Gazdar
The Oncologist 2002; 7: 451-457; doi:10.1634/theoncologist.7-5-451
[Abstract] [Full Text] [PDF]  

Combining Radiotherapy with Gene Therapy (From the Bench to the Bedside): A Novel Treatment Strategy for Prostate Cancer

Bin S. Teh, Estuardo Aguilar-Cordova, Maria T. Vlachaki, Laura Aguilar, Wei-Yuan Mai, James Caillouet, Maria Davis, Brian Miles, Dov Kadmon, Gustavo Ayala, Hsin H. Lu, J. Kam Chiu, L. Steven Carpenter, Shiao Y. Woo, Walter H. Grant, III, Thomas Wheeler, Timothy C. Thompson, E. Brian Butler
The Oncologist 2002; 7: 458-466; doi:10.1634/theoncologist.7-5-458
[Abstract] [Full Text] [PDF]  

The Molecular Perspective: Cadherin

David S. Goodsell
The Oncologist 2002; 7: 467-468; doi:10.1634/theoncologist.7-5-467
[Full Text] [PDF]  

Capitol Report

Marguerite Donoghue Baxter
The Oncologist 2002; 7: 469-470; doi:10.1634/theoncologist.7-5-469
[Full Text] [PDF]  

’Tis

Gregory A. Curt
The Oncologist 2002; 7: 471; doi:10.1634/theoncologist.7-5-471
[Full Text] [PDF]  

Photographs

John Dresser
The Oncologist 2002; 7: 471; doi:10.1634/theoncologist.7-5-471-a
[Full Text] [PDF]  

To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button.